Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEN26 Safety and PK in Healthy Participants
NCT05504746Phase 1Completed
- Sponsor
- Kexing Biopharm
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of obeldesivir in coronavirus disease 2019 (COVID-19), sponsored by Kexing Biopharm. Started Aug 2022; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05504746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504746.